STZ OcuTox develops and validates new in vivo models which can be used to select a lead compound for ophthalmic use, for proof of concept studies and to evaluate the efficacy of ocular drugs or medical devices.
STZ OcuTox sets up and validates new in vivo models according to the specific requirements of its clients. The same applies for the improvement of existing models.